Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333957 | 0.88 | NPC1 (0.61) | NOTUMRAB9ANPC1HDAC6 | |
| SCHEMBL25835003 | 0.84 | NOTUM (0.46) | KDM4ENOTUMRAB9ANPC1HDAC6 | |
| SCHEMBL23734594 | 0.82 | NOTUM (0.52) | KDM4ENOTUMRAB9ANPC1HSD17B1 | |
| SCHEMBL9681661 | 0.80 | NPC1 (0.55) | KDM4ENOTUMRAB9ANPC1MAPT | |
| SCHEMBL7829176 | 0.79 | RAB9A (0.60) | KDM4ENOTUMRAB9ANPC1MAPT | |
| SCHEMBL22862410 | 0.79 | RAB9A (0.60) | KDM4ENOTUMRAB9ANPC1MAPT | |
| SCHEMBL25699690 | 0.79 | NOTUM (0.52) | KDM4ENOTUMRAB9AALDH1A1 | |
| SCHEMBL28798361 | 0.79 | NOTUM (0.52) | KDM4ENOTUMRAB9ANPC1MAPT | |
| SCHEMBL8590849 | 0.79 | KDM4E (0.60) | KDM4ENOTUMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22598119 | 0.79 | NOTUM (0.44) | NOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | KDM4E 1852/4885NOTUM 4375/4885RAB9A 1179/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | KDM4E 2184/4885NOTUM 4727/4885RAB9A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.